At a glance

Fat loss / weight
Gastrointestinal discomfort
Pancreatitis / gallbladder risk
Thyroid C-cell tumour (contraindication)
Lean mass loss
Hypoglycaemia when combined· class-derived
BenefitSide effectHealth risk· more & brighter bars = stronger

Effects

  • Weight loss: mean reductions of roughly 15% to 21% of body weight in trials, depending on dose.[1]
  • Blood sugar: substantially lowers HbA1c in type-2 diabetes.[1]
Active half-life

~5 days (weekly)

Classification

GIP / GLP-1 receptor agonist

Route

Injectable (subcutaneous)